Trump’s FDA Pick Grilled on Priorities, Conflicts

//Trump’s FDA Pick Grilled on Priorities, Conflicts

Trump’s FDA Pick Grilled on Priorities, Conflicts

Mesh Medical Device News Desk, April 6, 2017 ~ President Trumps selection of Scott Gottlieb reveals a health industry insider full of potential conflicts. 

Dr. Scott Gottlieb was grilled during a confirmation hearing on Capitol Hill Wednesday and said his first priorities will include the opioid crisis.

Gottlieb is a medical doctor who turned to health consulting for the very industries he would regulate. It is the potential for financial conflicts-of-interest that a Senate health committee must reveal.  

The nominee is on the receiving end of thousands of dollars from companies involved in health care.  He also receives income from venture capital firms and investment bank involved in funding health care companies, according to the NY Daily News.

If confirmed, Gottlieb says he will recuse himself from decision involving GlaxoSmithKline and about 20 other companies. He would also have to resign his position on the board or as a consultant to nine other health care related companies.

Science will prevail at the agency with him at the head Gottlieb told Senators. As a cancer survivor, he says he understands the important role the FDA plays in public health.

Gottlieb stressed the importance of bringing new products to market, which is the constant criticism by industry of the agency, versus making sure good science guides the FDA in its decision making.

Opioid addiction could be addressed by finding non-addictive alternative painkillers, Gottlieb said.

Gottlieb, 44, was a deputy commission previously under the presidency of George W. Bush.

He currently is a fellow at the American Enterprise Insitute, a conservative nonprofit, from which he would resign. He is a frequent contributor of op-ed articles favoring drug and medical device firms.

Washington Sen. Patty Murphy

But Sen. Patty Murray of Washington, the committee’s senior Democrat, questioned whether recusals are enough to erase the bias of being a pharmaceutical industry insider when dozens of drugs being developed by those companies could come before the FDA.


“I want to earn the public’s trust,” Gottlieb reportedly said.

In other conversations Gottlieb voiced his disagreement with President Trump’s suggestion that vaccines may be linked to autism saying it’s been exhaustively studied and there is no causal link.  He said he is committed to tobacco control particularly in adolescents and e-cigarettes.



By |2017-04-06T09:30:26+00:00April 6th, 2017|FDA News|6 Comments

About the Author:

I’m National News Editor, Jane Akre and I began Mesh Medical Device News Desk aka Mesh News Desk (MND) in the summer of 2011 just after the Food and Drug Administration issued an explicit warning to the public that complications associated with surgical mesh used for prolapse repair (POP) and incontinence (SUI) are NOT rare! That was the starting point for the litigation you see today and thousands of lawsuits have been filed by women whose lives have been altered, some permanently, by the use of this petroleum-based product.


  1. daniee April 6, 2017 at 2:24 pm - Reply

    He does not qualify for the position…

  2. Victim Forever April 7, 2017 at 5:22 pm - Reply

    Another Trump humper…he will fit right in with big pharma…greed and the continuing loss of health advocacy for women…sad choice…sad for this country..

  3. Diva64 April 8, 2017 at 10:50 pm - Reply

    It is scary to put someone into this postion that is already so involved in the financial end and has received so much $$ from pharmaceutical companies . Really even though he was a doctor he left that for increased $$ , will he sell us out, or acknowledge that there has been a travesty in defective medical devices and stand up for us. This could definitely go either way. It is quite scary. Trump didn’t hesitate with going after those that injured the people of Syria with chemical warfare
    Will I say Mesh Polypropylene is a chemical warfare that has harmed will over 200,000 and counting. Will they stop this and support us.

    • Kitty April 10, 2017 at 8:09 am - Reply

      I agree it could go either way.

  4. Cholsakorn April 10, 2017 at 11:10 am - Reply

    Very bad idea..there will no more clinical trials for big pharma…straight to market….for sale just like the mesh mess same thing… no regulations …i cant even in my wildest imagination believe congress would allow…consumers will be the guinea pigs….

  5. Kitty April 22, 2017 at 8:45 am - Reply

    Mr Gottlieb should get down on his hands and knees and thank G-d that he had Doctors’ such as Dr David Weisman…noted palliative Oncologist fighting for Cancer patients and others in excruciating pain during the 80s 90s and 2000. It’s too bad that stoners and crackheads had to destroy this initiative. It was comforting to many many people knowing that their pain and anguish would be covered during their final days or years. I don’t know what kind of Cancer Mr Gottlieb had…but please leave the folks alone.

Leave A Comment